Abstract
The development of cancer immunotherapies has been a clinical exercise spanning nearly two decades with only one success to date, Dendreon’s Provenge® approval for prostate cancer. Although the path has been long, clinical challenges have been defined and resolutions have been proposed. This chapter aims to provide an understanding of cancer antigens, vaccine immune potentiators, and vaccine adjuvant systems currently under clinical development; new paradigms in clinical development; and biomarker discovery for vaccine development. Future trends in therapeutic vaccine strategies including the development of novel adjuvant systems, the utilization of oncolytic viruses as a means to “self-vaccinate,” and advances and hurdles of future prophylactic vaccines strategies are also described and assessed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
